BioTime Inc.

9.79+2.10+27.31%Vol 6.02M1Y Perf 115.41%
Apr 20th, 2021 16:00 DELAYED
BID9.55 ASK9.59
Open7.55 Previous Close7.69
Pre-Market- After-Market10.21
 - -  0.42 4.29%
Target Price
4.40 
Analyst Rating
— — 0.00
Potential %
-55.06 
Finscreener Ranking
★★★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
     23.89
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
     10.99
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap14.57M 
Earnings Rating
Buy
Price Range Ratio 52W %
84.24 
Earnings Date
18th May 2021

Today's Price Range

7.5010.95

52W Range

3.5910.95

5 Year PE Ratio Range

-16.10-3.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
61.29%
1 Month
-
3 Months
-
6 Months
-
1 Year
115.41%
3 Years
316.60%
5 Years
211.78%
10 Years
35.22%

TickerPriceChg.Chg.%
BTX9.792.100027.31
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
0.40
0.70
0.38
2.46
-31.00
Leverage Ratio 3.80
ProfitabilityValueIndustryS&P 500US Markets
45.20
-73.80
-40.90
-0.30
-93.86
RevenueValueIndustryS&P 500US Markets
3.41M
0.08
-33.88
-19.11
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.50-
Q02 2020--0.66-
Q01 2020--0.14-
Q04 2019--0.28-
Q03 2019--0.12-
Q02 2019-0.05-0.06-20.00
Q01 2019--0.11-
Q04 20180.150.11-26.67
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.060.00-
9/2019 QR-0.07-16.67Negative
12/2019 FY0.06125.00Positive
12/2020 FY-0.28-16.67Negative
Next Report Date18th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume6.02M
Shares Outstanding1.49M
Trades Count26.07K
Dollar Volume575.33K
Avg. Volume4.74M
Avg. Weekly Volume2.34M
Avg. Monthly Volume0
Avg. Quarterly Volume4.74M

BioTime Inc. (AMEX: BTX) stock closed at 9.79 per share at the end of the most recent trading day (a 27.31% change compared to the prior day closing price) with a volume of 6.25M shares and market capitalization of 14.57M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people. BioTime Inc. CEO is Brian M. Culley.

The one-year performance of BioTime Inc. stock is 115.41%, while year-to-date (YTD) performance is 964.13%. BTX stock has a five-year performance of 211.78%. Its 52-week range is between 3.59 and 10.95, which gives BTX stock a 52-week price range ratio of 84.24%

BioTime Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 10.47, a price-to-sale (PS) ratio of 93.73, a price to cashflow ratio of 7.20, a PEG ratio of 2.32, a ROA of -49.59%, a ROC of -72.41% and a ROE of -149.19%. The company’s profit margin is -93.86%, its EBITDA margin is -40.90%, and its revenue ttm is $3.41 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from BioTime Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BioTime Inc.’s next earnings report date is 18th May 2021.

The consensus rating of Wall Street analysts for BioTime Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for BioTime Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioTime Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioTime Inc. has a Neutral technical analysis rating based on Technical Indicators (ATR14 : 1.30, CCI20 : 106.12, Chaikin Money Flow : -0.33, Money Flow Index : 92.12, ROC : 106.72, RSI : 72.41, STOCH (14,3) : 75.93, Williams %R : -24.07), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioTime Inc. in the last 12-months were: Jeff Berg (Sold 145 000 shares of value $153 372 ), Robert S. Ellin (Sold 340 150 shares of value $1 891 878 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (16.67 %)
Hold
1 (16.67 %)
1 (16.67 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating---

BioTime Inc.

BioTime Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. BioTime's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells in clinical trial for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

CEO: Brian M. Culley

Telephone: +1 510 521-3390

Address: 1010 Atlantic Avenue, Alameda 94501, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

Bearish Bullish

50%50%

News

Stocktwits